{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.5","value":"59.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"}],"units":"Participants"}],"description":"Percent tumor necrosis by pathology review.","dispersionType":"Standard Deviation","groups":[{"description":"Intermediate \\& High Risk; Neoadjuvant chemoradiotherapy","id":"OG000","title":"Arm D"}],"paramType":"MEAN","populationDescription":"Only Arm D patients were evaluated at week 13 for percent tumor necrosis. Ineligible and inevaluable Arm D patients were excluded.","reportingStatus":"POSTED","timeFrame":"13 weeks","title":"Percent Tumor Necrosis","type":"SECONDARY","unitOfMeasure":"percentage of tumor necrosis"}